Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer
Paolo Tarantino(Harvard University), Sara M. Tolaney(Harvard University)
Cited by 0
Related Papers
HER2-Low Breast Cancer: Pathological and Clinical Landscape
|Journal of Clinical Oncology|2020|801
Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life
|Critical Reviews in Oncology/Hematology|2018|149
Enhancing Breast Cancer Risk Prediction with Machine Learning: Integrating BMI, Smoking Habits, Hormonal Dynamics, and BRCA Gene Mutations—A Game-Changer Compared to Traditional Statistical Models?
|Applied Sciences|2024|12
Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan
|Current Oncology Reports|2023|4